Improvement in Itch, Symptoms, and Quality of Life With Upadacitinib Through Week 16 in Adults and Adolescents With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)

被引：0
|
作者：
Lio, Peter [1 ]
Eichenfield, Lawrence F. [2 ,3 ,4 ]
Marcoux, Danielle [5 ]
Lee, Wan-Ju [6 ]
Teixeira, Henrique D. [6 ]
Raymundo, Eliza M. [6 ]
Gamelli, Amy E. [6 ]
Grada, Ayman [6 ]
Hu, Xiaofei [6 ]
Irvine, Alan D. [7 ,8 ]
机构：
[1] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Evanston, IL USA
[2] Univ Calif San Diego, Dept Dermatol, San Diego, CA USA
[3] Univ Calif San Diego, Dept Pediat, San Diego, CA USA
[4] Rady Childrens Hosp San Diego, San Diego, CA USA
[5] Univ Montreal, St Justine Univ Hosp Ctr, Div Dermatol, Dept Pediat, Montreal, PQ, Canada
[6] AbbVie Inc, N Chicago, IL USA
[7] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland
[8] Dermatol Childrens Hlth Ireland, Dublin, Ireland
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42065
引用
收藏
页码：AB178 / AB178
页数：1
相关论文
共 50 条
  • [21] Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Prajapati, Vimal H.
    Rosmarin, David
    Shumack, Stephen
    Calimlim, Brian M.
    Takemoto, Shunya
    Hu, Xiaofei
    Ladizinski, Barry
    Warren, Richard B.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E81 - E81
  • [22] Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study
    Magnolo, Nina
    Cameron, Michael C.
    Shahriari, Mona
    Geng, Bob
    Calimlim, Brian M.
    Teixeira, Henrique
    Hu, Xiaofei
    Yang, Yang
    Liu, Yingyi
    Zhang, Shiyu
    Sanchez, Cristina Sancho
    Altman, Katherine
    Langley, Richard G.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [23] The effect of upadacitinib on the genital region in moderate-to-severe atopic dermatitis: an analysis from the Measure Up 1 and Measure Up 2 studies
    Cather, Jennifer
    Magnolo, Nina
    Cameron, Michael
    Calimlim, Brian
    Lane, Michael
    Hays, Stephanie
    Gamelli, Amy
    Woo, Yu Ri
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [24] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
    Simpson, E. L.
    De Bruin-Weller, M. S.
    Prajapati, V. H.
    Calimlim, B. M.
    Teixeira, H. D.
    Zeng, J.
    Liu, M.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E124
  • [25] Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
    Simpson, Eric L.
    Prajapati, Vimal H.
    Leshem, Yael A.
    Chovatiya, Raj
    de Bruin-Weller, Marjolein S.
    Staender, Sonja
    Pink, Andrew E.
    Calimlim, Brian M.
    Lee, Wan-Ju
    Teixeira, Henrique
    Ladizinski, Barry
    Hu, Xiaofei
    Yang, Yang
    Liu, Yingyi
    Liu, Meng
    Grada, Ayman
    Platt, Andrew M.
    Silverberg, Jonathan I.
    DERMATOLOGY AND THERAPY, 2024, 14 (05) : 1127 - 1144
  • [26] EFFECT OF UPADACITINIB ON INTENSITY OF SCORAD ITEMS AND IMPACTS TO ITCH AND SLEEP: ANALYSIS FROM THE MEASURE UP 1 AND MEASURE UP 2 STUDIES
    Cameron, Michael
    Magnolo, Nina
    Prajapati, Vimal H.
    Haque, Adel
    Lee, Wan-Ju
    Altman, Katherine
    Platt, Andrew M.
    Lane, Michael C.
    Calimlim, Brian M.
    Taieb, Alain
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 56 - 57
  • [27] Achieving incrementally greater skin improvement thresholds with upadacitinib in moderate-to-severe atopic dermatitis: a pooled analysis of two phase III studies (Measure Up 1 and Measure Up 2)
    Reich, K.
    Langley, R. G.
    Calimlim, B. M.
    Teixeira, H. D.
    Zeng, J.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E131 - E132
  • [28] Ef-ficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD UpRandomized Clinical Trials
    Paller, Amy. S.
    JAMA DERMATOLOGY, 2024, 160 (05) : 582 - 582
  • [29] The multidimensional burden of moderate-to-severe atopic dermatitis: a pooled analysis of baseline data from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Silverberg, J. I.
    Thyssen, J. P.
    Costanzo, A.
    Calimlim, B. M.
    Tenorio, A. R.
    Chen, N.
    Gooderham, M. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E126 - E127
  • [30] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
    Guttman-Yassky, Emma
    Teixeira, Henrique D.
    Simpson, Eric L.
    Papp, Kim A.
    Pangan, Aileen L.
    Blauvelt, Andrew
    Thaci, Diamant
    Chu, Chia-Yu
    Hong, H. Chih-Ho
    Katoh, Norito
    Paller, Amy S.
    Calimlim, Brian
    Gu, Yihua
    Hu, Xiaofei
    Liu, Meng
    Yang, Yang
    Liu, John
    Tenorio, Allan R.
    Chu, Alvina D.
    Irvine, Alan D.
    LANCET, 2021, 397 (10290): : 2151 - 2168
12345